Product and MoA

We are developing Imgatuzumab, a humanized, glycoengineered, anti-EGFR monoclonal antibody (mAb) with enhanced Antibody Derived Cell Cytotoxicity (ADCC) and (Antibody Derived Cell Phagocytosis (ADCP) properties, for the treatment of solid tumors.

A Ph1/2 Imgatuzumab development program by Roche, involving in total 296 patients, demonstrated Imgatuzumab monotherapy activity in a variety of relapsing/refractory EGFR+ cancers, including patients with colon/rectum cancer with mutant KRAS and patients with prior anti-EGFR therapy.[1]

The technology is based on defucosylation of the Fc region of the antibody, inducing a higher affinity to Fc gamma receptors located on immune effector cells.

The Roche clinical development program established a well understood activity and safety profile of imgatuzumab monotherapy against EGFR expressing tumors. Toxicities arising from imgatuzumab treatment are characteristic for anti-EGFR monoclonal antibodies, like cetuximab. No new toxicities occurred for Imgatuzumab.  
   

[1]Paz-Ares, L.G., et al. 2011